Complete Full Cohort Ph 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent NSCLC Announced September 22, 2026
Updated Data from Ph 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of BH-30643 in EGFR C797S-Positive NSCLC Presented September 22, 2026
SYS6010 granted breakthrough therapy designation by NMPA in China for patients with actionable genomic alteration-negative non-squamous NSCLC September 22, 2026
FDA approves supplemental NDA for IBTROZI® (taletrectinib) for the treatment of locally advanced or metastatic ROS1+ NSCLC September 22, 2026
KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for SubQ Administration for All KEYTRUDA Indications Approved in Japan September 22, 2026
Gotistobart Nearly Doubled Median OS versus SOC Chemo in Previously Treated Squamous NSCLC Patients September 16, 2026
Zipalertinib + chemo Demonstrates 6-Month Median PFS Benefit in REZILIENT3 Ph 3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC September 16, 2026
Complete Full Cohort Ph 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent NSCLC Announced September 16, 2026
Positive results announced from registrational Ph 1/2 ARROS-1 trial of Jideytro (zidesamtinib) in patients with advanced or metastatic TKI-naive ROS1-positive NSCLC September 16, 2026
RYBREVANT® (amivantamab-vmjw) + chemo delivers long median OS in EGFR exon 20 insertion mutation-positive NSCLC September 16, 2026
Enhertu demonstrated a median PFS of 14.3 months IN 1L HER2-mutant advanced NSCLC in DESTINY-Lung04 Ph 3 trial September 16, 2026
NEJM Publishes Ph 1/2 Clinical Data on RASONQUE™ (daraxonrasib) in Metastatic NSCLC September 9, 2026
Ivonescimab Meets OS Key Secondary Endpoint in Interim Analysis of Ph 3 HARMONi-2 Study, Demonstrating Statistically Significant Benefit Versus Pembrolizumab in 1L PD-L1-Positive NSCLC September 9, 2026
FDA Fast Track Designation for BH-30643 for the Treatment of Advanced EGFR C797S-positive NSCLC August 25, 2026
Zipalertinib + Chemo Meet Primary PFS Endpoint in Planned Interim Analysis of Ph 3 REZILIENT3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC August 20, 2026
Enhertu demonstrated statistically significant and clinically meaningful PFS improvement in HER2-mutant NSCLC in DESTINY-Lung04 Ph 3 trial August 20, 2026
IDMC recommends discontinuing the eVOLVE-Lung02 Ph 3 trial of volrustomig + chemo in 1L metastatic NSCLC with PD-L1 <50% August 20, 2026
Final ASTRUM-002 Analysis Shows Survival Benefit with Hetronifly in Advanced non squamous NSCLC After Four Years of Follow-Up August 20, 2026
Ivonescimab + Chemo Approved in China by NMPA for 1L Treatment of Patients with Squamous NSCLC August 20, 2026
ACR-2316 advances into dose expansion portion of Ph 1/2 study in SCLC, squamous NSCLC, lung adenocarcinoma (adNSCLC), endometrial, cervical, and GEJ cancers August 11, 2026
Ivonescimab + Chemo Shows Consistent, Favorable OS Results in Western and Asian Patients in Updated Analysis from Global Ph 3 HARMONi Study July 28, 2026